Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9Metastatic Castration-resistant Prostate Cancer 2Urogenital Neoplasms 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Neoplasms, Male 1

Interventions

pembrolizumab 2radium Ra 223 dichloride 1enzalutamide 1efineptakin alfa 1abiraterone 1Radium-223 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Injections 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Pluvicto × Clear all
NCT04825652 2023-01-13

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Advanced Accelerator Applications

No longer available
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡